Maxim analyst Jason McCarthy initiated coverage of Cero Therapeutics (CERO) with a Buy rating and $3 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERO:
- CERo Therapeutics Regains Nasdaq Compliance with Stockholder Equity
- Cero Therapeutics regains compliance with Nasdaq
- Cero announces TriStar Centennial as trial site for Phase 1 study of CER-1236
- CERo Therapeutics Files Series D Stock Designations
- Cero Therapeutics to present on CER-1236 at ASCO meeting